Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of advanced liver cancer adequate bone marrow, liver and kidney function~* Any local therapy for tumor must have been completed at least 4 weeks prior to enrolling in study~Exclusion criteria:~* Pregnant or breastfeeding~* Any serious or unstable medical or psychiatric conditions~* History of metastases to central nervous system~* History of ulcer, inflammatory bowel disease or disease of the gut~* History of HIV, or uncontrolled infection~* Have had a cardiac condition or stoke during the past 6 months~* High blood pressure~* Have had a blood clot during the past 6 months~* History of bleeding blood vessels

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib Arm (Type: EXPERIMENTAL): Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.

Based on this trial design, predict the completion outcome and termination type (if applicable).